Ann: Investor Presentation, page-11

Thanks for the post Kain.

As the information gets out the medical industry in the US, driven by the insurance companies (Aussies don't realise how much insurance rebates schedules drive private medicine in Australia too - cardiology, endoscopies and optical have more generous schedules and are popular facets of private medicine business in Australia because of the ease of revenues/payments), the use of Striate+ is only going to accelerate.

When US medical insurance firms (and patients) realise that using BioHorizons/Orthocells' Striate product Striate+ allows a single-stage dental procedure instead of two-stage to single-stage dental procedures versus say Struamann's Cerabone for example (the leading US dental bio-graft), reducing the procedure time by several months (and more importantly for insurance companies, reducing costs), Striate is quickly going to move to the top of the preference list for dental graft membranes. Its actually likely to be a game changer and other products would have to match. Are you choosing a two stage treatment over a one stage treatment as a patient, the single stage treatment option arguably offering better efficacy too?

The only stakeholder wanting a two stage procedure is the Dentist. They do not drive the US market. Insurance companies and patients do. Anyone who has turned on a TV in the US will attest to the sheer volume of drug/medical product ads that drive the market demand.